RE:RE:ZzzzzzzWith the new CV19 variants spreading around it looks like SONAs testing will have to be done again to prove it can detect the new variants. Since SONAs test test the Spike Protein and the mutated Cv19 viruses changes in the Spike protein it does not look good.
Tests use to detect the variant strains, first emerging in the United Kingdom and in South Africa, targeting the nucleocapsid protein on the SARS-Cov-2 coronavirus are likely unaffected. Since the majority of the mutations appearing to date are of the spike protein.
Thus researchers continue to monitor the situation closely and do not anticipate efficacy concerns with the variants that have occurred thus far for tests that target the N protein.. MikeyH wrote: If any major contracts had been signed SONA would have issued a NR immediately to stem the stock price bleed. Anyone who thinks otherwise is living in cloud cuckoo land.
The lawsuits are interesting, but I agree won't go anywhere. SONA's NRs have been generally crappy and poorly written, but not wholly misleading. Ambulance chasers for sure